齐拉西酮治疗精神分裂症随机双盲对照研究

Ziprasidone in treatment of schizophrenia:a randomized,double-blind,parallel control study

目的:评价齐拉西酮治疗精神分裂症的疗效及安全性。方法:160例首次发作精神分裂症患者随机分为齐拉西酮组和利培酮组各80例。分别给予齐拉西酮和利培酮治疗,进行为期6周的双盲对照研究。采用阳性和阴性症状量表(PANSS)、临床疗效总评量表(CGI)、治疗中出现的症状量表(TESS)评价疗效和安全性。结果:两组PANSS评分在治疗后的各个周期均较治疗前显著降低(P均<0.01);PANSS减分率齐拉西酮组平均(65.3±21.1)%,利培酮组平均(67.0±19.3)%;两组疗效差异无显著性(P>0.05)。两组不良反应发生率相当(P>0.05)。结论:齐拉西酮治疗精神分裂症的疗效及安全性与利培酮相当。

Objective：To examine the efficacy and safety of domestic ziprasidone on schizophrenia. Method：160 patients with first onset schizophrenia were randomly assigned to receive either ziprasidone （n=80） or risperidone （n=80） for six weeks.The treatment effect was assessed using positive and negative syndrome scale （PANSS）,clinical global impression （CGI） and treatment emergent symptom scale （TESS）. Results：By the end of the treatment,the scores of PANSS in both groups decreased significantly compared to the baseline （P0.01）,with the reduction rates of （65.3±21.1）% in ziprasidone group and （67.0±19.3）% in risperidone group.Ziprasidone group did not show significant different clinical effective rates from risperidone group （P0.05）.No significant difference was found in adverse reactions between the two groups （P0.05）. Conclusion：Zipradidone has similar efficacy to risperidone in treatment of schizophrenia.